That chemotherapy is not indicated to all breast cancer cases?

Prosigna™ (PAM50) is a genetic test indicated for women with early hormone receptor-positive invasive breast cancer. From the genetic analysis of the tumor, the patient will be classified into risk groups (high, Intermediate and low risk) that will aid in the decision of the treatment.

With Prosigna™ (PAM50) physicians will be able to identify patients who will actually benefit from chemotherapy and hormone extended therapy, sparing those patients whose more aggressive treatment will not help cure the disease but will bring about risks and undesirable side effects.

Approved by the regulatory agencies of the United States - Food and Drug Adminstration (FDA) and Europe - European Medicine Agency (EMA) as a prognostic tool in early breast cancer. In addition, it was recommended by the Saint Gallen Consensus and the ESMO - European Society for Medical Oncology, and recently by the American Society of Clinical Oncology (ASCO). It is also being validated by the National Comprehensive Cancer Network (NCCN).

Treatment customization of
breast cancer, it is possible!

How can I order Prosigna™?
Step one: ask your doctor and make sure Prosigna™ is right for you.
Then contact IntelligeneCG and request the form and consent form. These two documents should come with the material to be analyzed.

The material used will be the same extracted from the surgery already performed on the patient.